The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Top Cited Papers
Open Access
- 17 November 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is associated with the pathogenesis of inflammatory diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Interleukin-23 (IL-23) plays a pivotal role in stimulating the production of IL-17 by activating the Th17 cells. The IL-23/IL-17 axis is an important pathway for targeted therapy for inflammatory diseases. Emerging evidence from clinical trials has shown that monoclonal antibodies against IL-23, IL-17, and tumor necrosis factor are effective in the treatment of patients with psoriasis, atopic dermatitis, hidradenitis suppurativa, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Here, we summarize the latest knowledge about the biology, signaling, and pathophysiological functions of the IL-23/IL-17 axis in inflammatory skin diseases. The currently available biologics targeting the axis is also discussed.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (81972931 to HF, 2020KY558 to JQ, LY20H110001 to YL)
This publication has 170 references indexed in Scilit:
- Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin InflammationImmunity, 2011
- Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)Nature Immunology, 2011
- The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammationNature Immunology, 2011
- SEF/IL-17R (SEFIR) Is Not EnoughOnline Journal of Public Health Informatics, 2010
- Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokinesThe Journal of Experimental Medicine, 2010
- Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigenJournal of Allergy and Clinical Immunology, 2009
- Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis PathogenesisJournal of Investigative Dermatology, 2009
- IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cellsJournal of Allergy and Clinical Immunology, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008